New FDA Approved PARP Inhibitor: Talzenna (Talazoparib) & Xtandi | #markscholzmd #AlexScholz #pcri
New FDA Approved PARP Inhibitor: Talzenna (Talazoparib) & Xtandi | #markscholzmd #AlexScholz #pcriSee more
New FDA Approval: Darolutamide for Hormone-Sensitive Disease | Mark Scholz, MD | PCRISee more
The Four Levels of #ProstateCancer Treatment Intensity | #markscholzmd #alexscholz @ThePCRISee more
Lupron vs Eligard, Trelstar and Others | #MarkScholzMD #AlexScholz #PCRISee more
Metastatic #ProstateCancer Treatment Case Study | #MarkScholzMD #AlexScholz #PCRISee more
Advanced #ProstateCancer Treatments + Extended Q+A | #MarkScholzMD & #MarkMoyadMD #PCRISee more
#ProstateCancer Diagnosis Over 80 Years Old | #MarkScholzMD #AlexScholz | #PCRISee more
Talazoparib plus enzalutamide shows improvement in PFS over SOC in first-line HRR mCRPCSee more
Does #ProstateCancer Tumor Size and Location Matter? | #MarkScholzMD #AlexScholz | #PCRISee more
How Much Time Do You Have to Treat #ProstateCancer? | #MarkScholzMD #AlexScholz #PCRISee more
How PSA Responds to #ProstateCancer Treatment | #MarkScholzMD #AlexScholz #PCRISee more
Osteoporosis: Treatments & Preventing Fractures | #MarkScholzMD #AlexScholz #PCRISee more
PSMA & Newly-Diagnosed #ProstateCancer | MarkScholzMD #AlexScholz #PCRISee more
#ProstateCancer Treatments: Earlier Rather Than Later? | #markscholzmd #alexscholz @ThePCRISee more
Treating Side Effects of Hormone Therapy | #MarkScholzMD #AlexScholz #PCRISee more
Do You Know Your Testosterone Levels? | Symptoms & Testing | #MarkScholzMD #AlexScholz #PCRISee more
Novel combination therapy regimen shows promising results for prostate cancerSee more
Orchiectomy vs. Hormone Therapy | #MarkScholzMD #AlexScholz #PCRISee more
Comparing the Second Generation Hormone Therapies | Ask a Prostate Expert, Mark Scholz, MDSee more
IMRT vs. SBRT & Reducing Radiation Toxicity | #MarkScholzMD #AlexScholz #PCRISee more
